Harnessing GenAI: Opportunities for Health Care & Life Sciences
Data privacy and security are paramount in highly regulated industries.
Generative AI stands as a beacon of innovation in the health care and life sciences sectors. To explore its implementation and potential, data and AI leader SAS alongside Coleman Parkes Research surveyed 477 leaders across life sciences and health care, examining their strategies for integrating GenAI, data, and analytics.
Health Care Embracing GenAI Innovations
The findings show that health care leaders are optimistic about GenAI's transformative capabilities. Here are some insights:
- Current Adoption: 46% of health care organizations currently utilize GenAI, slightly below the average of 54% across all sectors.
- Future Plans: A striking 95% of health care organizations plan to adopt or already use GenAI within two years.
- Investment Outlook: 87% intend to invest in GenAI in the next financial year, with 92% allocating a budget specifically for GenAI initiatives.
- Top Outcomes: Organizations already using GenAI highlight efficiency in data processing as the primary milestone, achieving 89% success in this area, along with 88% reporting advancements in risk management and compliance.
Alyssa Farrell, Global Health and Life Sciences Industry Marketing Director at SAS, shared, "The challenges and diverse functions of the health care sector demand special consideration regarding regulatory compliance, data sensitivity, and bias in AI algorithms. The adoption of GenAI in health care will likely accelerate as these issues are addressed."
Life Sciences on the Brink of Transformation
In life sciences, the study revealed a significant engagement with the technology:
- Current Usage: 58% of organizations within this sector are already utilizing GenAI.
- Future Adoption: 97% of life sciences organizations are on track to adopt or are currently using GenAI technologies.
- Financial Commitment: 85% aim to invest in GenAI, with a considerable 92% of those companies establishing a dedicated budget for the upcoming year.
- Efficiency Gains: 86% report enhanced efficiency in processing large datasets, while 79% have noted reductions in operational costs and time.
Farrell also remarked that the life sciences sector is poised for significant advancements facilitated by GenAI, confidently stating, "The technology’s predictive capabilities suggest profound potential to accelerate initiatives across the R&D, clinical trials, and commercialization phases."
Addressing Data Privacy and Security Concerns
As GenAI technology evolves, leaders must navigate data privacy and security challenges unique to health care and life sciences. The study highlighted critical concerns:
- Leadership Concerns: 79% of life sciences leaders and 77% of health care leaders expressed discomfort regarding data privacy and security in their organizations.
- Governance Issues: Governance stands as a leading GenAI concern for 62% of health care organizations and 59% of life sciences entities, marking a higher percentage than most other industries.
- Established Framework Weakness: Only 14% of life sciences leaders and 9% of health care leaders described their AI governance frameworks as well-established and comprehensive.
Utilization of Synthetic Data
Synthetic data is gaining traction as a solution to data-related challenges. It can replace or complement real-world data and simulate patient workflows or supply chains. The GenAI study indicates a growing acceptance of synthetic data in both sectors:
- Current Usage: 56% of life sciences organizations and 46% of health care entities are either utilizing or contemplating the use of synthetic data.
According to Farrell, "Data is the lifeblood of the digital health ecosystem. Continuing to invest in interoperability and data governance is crucial, paving the way for a GenAI future. Embracing synthetic data technology, alongside concepts like digital twins, maximizes the value derived from data for improved patient and population health outcomes."
Join the Conversation at SAS Innovate
For those eager to learn more about data and AI innovations in health care and life sciences, SAS Innovate promises insightful discussions. The event is scheduled for May 6 – 9 in Orlando, featuring a detailed agenda focusing on industry-specific advancements.
About SAS
SAS is a recognized leader in data and AI. By employing SAS software and customized industry solutions, organizations can convert data into well-informed decisions. SAS empowers entities with resources to enhance their operations.
Frequently Asked Questions
What is the main focus of the global GenAI study?
The study focuses on assessing how health care and life sciences organizations are implementing Generative AI to improve outcomes and manage challenges.
What percentage of health care organizations currently use GenAI technology?
46% of health care organizations are currently utilizing GenAI technology.
What are common concerns regarding GenAI among leaders in health care?
Data privacy and security are leading concerns, with many leaders feeling uneasy about these aspects of GenAI integration.
How is synthetic data being utilized in these sectors?
Synthetic data is increasingly being adopted to address data challenges and can effectively represent original data without compromising sensitive information.
What insights did SAS provide on the future of GenAI in life sciences?
SAS emphasizes that life sciences organizations are expected to continue enhancing their use of GenAI, focusing on innovative capabilities and maintaining competitive advantages.
